Biopharma Business

Tag "Xeljanz"

Pfizer’s Xeljanz Authorized for Marketing in the European Union

Xeljanz (tofacitinib citrate) receives marketing authorization in the European Union for the treatment of moderate to severe active rheumatoid arthritis (RA). Pfizer Inc. announced today that the European Commission (EC)

Read Full Article

Upcoming Events


The Magazine

New Subscriber

Subscribe Here